Table 1.
Demographic, antibody, and nucleic acid detection characteristics of 27 patients infected with SARS-CoV-2.
| No. | Age range | Course of diseasea | Symptoms | IgM | IgG | Swab PCR | Breath PCR |
|---|---|---|---|---|---|---|---|
| 1* | 60–65 | 42/46 | – | + | + | – | – |
| 2* | 50–55 | 29/33 | – | + | + | + | – |
| 3 | 70–75 | 47 | Cough, shortness of breath after activity | + | + | – | – |
| 4 | 70–75 | 52 | – | – | + | + | – |
| 5* | 60–65 | 51/55 | – | + | + | + | – |
| 6* | 70–75 | 52/56 | – | – | + | – | – |
| 7* | 40–45 | 23/27 | – | + | + | + | – |
| 8* | 25–30 | 45/49 | – | + | + | + | – |
| 9* | 60–65 | 49/53 | – | – | + | – | – |
| 10* | 75–80 | 52/56 | Mild shortness of breath after activity | – | + | – | – |
| 11* | 55–60 | 54/58 | Mild cough, shortness of breath after activity | – | + | – | – |
| 12 | 60–65 | 28 | – | + | + | + | – |
| 13 | 40–45 | 56 | – | + | + | + | – |
| 14 | 65–70 | 54 | – | + | + | – | – |
| 15 | 65–70 | 45 | – | + | + | – | – |
| 16 | 60–65 | 47 | – | + | + | – | – |
| 17 | 70–75 | 56 | – | + | + | – | – |
| 18 | 50–55 | 48 | – | + | + | – | – |
| 19 | 40–45 | 70 | – | + | + | – | – |
| 20 | 40–45 | 48 | – | + | + | – | – |
| 21 | 50–55 | 55 | – | + | + | – | – |
| 22 | 70–75 | 55 | – | + | + | – | – |
| 23 | 50–55 | 46 | – | + | + | – | – |
| 24 | 40–45 | 33 | – | + | + | – | – |
| 25 | 50–55 | 36 | Cough, expectoration | + | + | + | + |
| 26 | 60–65 | 52 | – | + | + | + | + |
| 27 | 60–65 | 63 | – | – | + | + | + |
| 28 | 35–40 | – | – | ||||
| 29 | 35–40 | – | – | ||||
| 30 | 40–45 | – | – | ||||
| 31 | 35–40 | – | – | ||||
| 32 | 40–45 | – | – | ||||
| 33 | 35–40 | Epidemiological status: never travelled to the epidemic area and never were physically close to COVID-19 patients. COVID-19 symptoms: none. |
– | – | |||
| 34 | 25–30 | – | – | ||||
| 35 | 30–35 | – | – | ||||
| 36 | 45–50 | – | – | ||||
| 37 | 35–40 | – | – | ||||
| 38 | 45–50 | – | – | ||||
| 39 | 30–35 | – | – | ||||
a
Lung CT scans were taken every week before breath sampling, where all patients showed decreased glass shadows; swab PCR and routine blood tests were performed within 3 d before expiratory sampling; and antibody testing was performed within 7 d before expiratory sampling.
“–”: no clinical symptoms/negative result; “+”: positive result; “*”: had two tests within 4 days apart but without a difference in results. The positive breath samples were further analysed by standard curve qPCR to determine the virus concentration (Nos. 25–27, shown in grey background).